Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of Oral FXR Modulator EYP001a Combined With Nucleos(t)Ide Analogues (NA) in Virologically Suppressed Chronic Hepatitis B Patients to Improve Functional Cure Rates

Next Previous
Trial Profile

A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of Oral FXR Modulator EYP001a Combined With Nucleos(t)Ide Analogues (NA) in Virologically Suppressed Chronic Hepatitis B Patients to Improve Functional Cure Rates

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vonafexor (Primary) ; Entecavir; Tenofovir
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors ENYO Pharma

Most Recent Events

  • 21 Sep 2022 Status changed from active, no longer recruiting to discontinued.
  • 30 Jul 2021 Interim results presented in an ENYO Pharma media release.
  • 30 Jul 2021 According to an ENYO Pharma media release, an interim analysis conducted by the DSMC concluded that Vonafexor was well tolerated and safe but there was no apparent efficacy benefit of Vonafexor with Entecavir. Therefore, no additional patients will be recruited in this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top